![]() Lin CW, Lin IH, Chen TC, Jou JR, Woung LC. Demographic and clinical features of neuromyelitis optica: a review. Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, et al. ![]() Matiello M, Kim HJ, Kim W, Brum DG, Barreira AA, Kingsbury DJ, et al. Racial differences in neuromyelitis optica spectrum disorder. Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. 2022 70:1771–9.įlanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, et al. Incidence and prevalence of neuromyelitis optica spectrum disorders in the background of international consensus diagnostic criteria-a systematic review. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. Demyelinating disease: NMO spectrum disorders: clinical or molecular classification? Nat Rev Neurol. Is neuromyelitis optica distinct from multiple sclerosis?: something for “lumpers” and “splitters”. Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial. 2015 2:e89.Ĭhen JJ, Tobin WO, Majed M, Jitprapaikulsan J, Fryer JP, Leavitt JA, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Waters P, Woodhall M, O’Connor KC, Reindl M, Lang B, Sato DK, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. Diagnosis and classification of optic neuritis. Petzold A, Fraser CL, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, et al. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. This review will summarise the characteristic neuro-ophthalmological signs in NMOSD and MOGAD, serological markers and radiographic findings, as well as acute and long-term therapies used for these disorders.īeck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, et al. The severity, rate of recurrence and overall outcome differs in these two entities requiring prompt and accurate diagnosis and management. These disorders are associated with atypical ON that was not well characterised in the ONTT. However, since the completion of the ONTT, there has been the discovery of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) antibodies, which are biomarkers for neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody-associated disease (MOGAD), respectively. Typical ON is often idiopathic or seen in patients with multiple sclerosis, which is well described in the landmark clinical trial, the Optic Neuritis Treatment Trial (ONTT). Optic neuritis (ON) is one of the most frequently seen neuro-ophthalmic causes of vision loss worldwide.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |